About the Authors
- Myint Tin Tin Htar
-
Contributed equally to this work with: Myint Tin Tin Htar, Anke L. Stuurman
* E-mail: Myint.TinTinHtar@pfizer.com
Affiliation Pfizer: Vaccines Clinical Epidemiology, Pfizer Inc, Paris, France
- Anke L. Stuurman
-
Contributed equally to this work with: Myint Tin Tin Htar, Anke L. Stuurman
Affiliation P95 Epidemiology and Pharmacovigilance Consulting and Services, P95, Leuven, Belgium
- Germano Ferreira
-
Affiliation P95 Epidemiology and Pharmacovigilance Consulting and Services, P95, Leuven, Belgium
- Cristiano Alicino
-
Affiliation Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy
- Kaatje Bollaerts
-
Affiliation P95 Epidemiology and Pharmacovigilance Consulting and Services, P95, Leuven, Belgium
- Chiara Paganino
-
Affiliation Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy
- Ralf René Reinert
-
Affiliation Pfizer: Vaccines Medical Development and Scientific Clinical Affairs, Pfizer Inc, Paris, France
- Heinz-Josef Schmitt
-
Affiliation Pfizer: Vaccines Medical Development and Scientific Clinical Affairs, Pfizer Inc, Paris, France
- Cecilia Trucchi
-
Affiliation Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy
- Thomas Vestraeten
-
Affiliation P95 Epidemiology and Pharmacovigilance Consulting and Services, P95, Leuven, Belgium
- Filippo Ansaldi
-
Affiliation Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy
Competing Interests
Pfizer is the manufacturer of one of the two pneumococcal vaccines indicated for adults (PCV13), and for which no real-world evidence was found in this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: MTTH GF ALS TV. Data curation: ALS GF. Formal analysis: GF KB. Funding acquisition: MTTH. Investigation: ALS GF KB MTTH. Methodology: ALS GF MTTH KB. Project administration: GF MTTH. Resources: MTTH AS GF KB. Software: GF KB. Supervision: GF MTTH. Validation: GF. Visualization: GF KB. Writing – original draft: ALS MTTH. Writing – review & editing: MTTH ALS GF CA KB CP RRR HJS CT TV FA.